Video

Dr. Schuster on GO29781 Trial With Mosunetuzumab in NHL

Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

New drugs for patients with B-cell lymphomas, including large B-cell lymphomas (LBCL), aggressive NHLs, and indolent NHLs, continues to be an unmet need, says Schuster.

Mosunetuzumab is a new bispecific antibody that binds to CD20 on B cells and CD3 on T cells. The agent is designed to eradicate B cells with a patient’s T cells, explains Schuster. GO29781 enrolled patients with LBCL—mainly diffuse large B-cell lymphoma, but also follicular lymphoma and mantle cell lymphoma. The study also accrued patients with more indolent lymphomas, adds Schuster.

In the study, investigators evaluated the tolerability, toxicity, maximum-tolerated dose, and efficacy of the drug. Notably, objective responses were observed in both aggressive and indolent lymphomas across all dose levels. Additionally, patients who did not respond to CAR T-cell therapy achieved a similar response rate to those with aggressive lymphomas who had not received prior CAR T-cell therapy, concludes Schuster.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS